Start Your Search
EP1.01 - Advanced NSCLC (ID 150)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Advanced NSCLC
- Presentations: 1
- Now Available
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
EP1.01-70 - Reirradiation for Locoregionally Recurrent Lung Cancer: Outcomes in Non-Small Cell Lung Carcinoma (Now Available) (ID 1848)
08:00 - 18:00 | Author(s): Parag Roy
Locoregional failure in non-small cell lung cancer (NSCLC) remains high often leading to symptoms like hemoptysis and chest pain and the management for recurrent disease in the setting of prior radiotherapy is difficult. We retrospectively analyzed the outcomes for re-irradiation (reRT) for locoregionally recurrent lung cancer when used with intention of symptomatic relief in NSCLC.Method
This is a retrospective analysis of treatment of thirty-four patients of NSCLC who received re-irradiation to the thorax. All received re-irradiation by intensity-modulated radiotherapy. Palliative responses, survival outcomes, and prognostic factors were analyzed.Result
Median age of the group was 63 years, all but seven patients were males. All patients received a dose of 30.6 Gy in 17 fractions. Median survival of the group was 4.7 months, median KPS was 70. Relief of haemoptysis could be obtained in 31/34 assessable cases (91%), treatment was less effective for coughing 19/34 (56%) and dyspnoea 11/34 (32%). However, acute toxicities and new disease symptoms limited the duration of palliative benefit in the symptomatic NSCLC patients to a median of 2.3 months. No fatal complications were noted . Grade 2 or greater esophagitis was seen in 3/34(8%) cases.Conclusion
Reirradiation to the thorax for locoregionally recurrent NSCLC can provide palliative benefit. Select patients may experience meaningful survival prolongation after reirradiation. Careful selection of patients is necessary to avoid acute toxicity in already symptomatic patients. This experience demonstrates that repeated courses of radiotherapy can be given successfully and safely despite previous radical dosage.
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.